Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae
bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in
combination with aztreonam (ATM) against Metallo-β-lactamases (MBL) producing
Enterobacterales in vivo. The investigators then use CRISPR/Cas9 technology to remove
Enterobacteriaceae bacteria resistance and virulence genes